Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Rhea-AI Summary

Telesis Bio Inc. (NASDAQ: TBIO) has announced its decision to voluntarily delist its common stock from the Nasdaq Global Select Market. The company plans to file a Form 25 with the SEC on or about September 20, 2024, with the last trading day expected to be around September 30, 2024. This decision comes after Telesis received notifications from Nasdaq regarding non-compliance with the minimum stockholder's equity requirement and the minimum Market Value of Publicly Held Shares (MVPHS) requirement.

Telesis believes it will be unable to regain compliance with these requirements. Following the delisting, the company's common stock is expected to be quoted on an OTC market, although there is no guarantee of continued trading. Telesis will remain subject to reporting obligations under the Exchange Act.

Positive

• None.

Negative

• Voluntary delisting from Nasdaq Global Select Market
• Non-compliance with minimum stockholder's equity requirement ($10 million)
• Failure to meet minimum Market Value of Publicly Held Shares ($5 million)
• Potential loss of investor confidence and market visibility
• Possible reduced liquidity for shareholders
• Uncertainty about future trading on OTC markets

Insights

Financial Analyst

Telesis Bio's decision to delist from Nasdaq is a significant negative development for the company and its shareholders. This move typically indicates severe financial distress or inability to meet listing requirements. The company's failure to maintain the required $10 million in stockholders' equity and $5 million market value of publicly held shares suggests substantial financial challenges.

Delisting often results in reduced liquidity and decreased investor interest, potentially leading to further share price declines. The transition to OTC markets may limit institutional investment and make it harder for the company to raise capital. This could impair Telesis Bio's ability to fund operations and pursue growth opportunities in the competitive RNA and DNA solutions market.

Market Research Analyst

The delisting of Telesis Bio from Nasdaq could have ripple effects across the biotech sector. It may signal broader challenges in the RNA and DNA synthesis technology market, potentially impacting investor sentiment towards similar companies. This move might also reduce Telesis Bio's visibility and credibility among potential customers and partners in the research community.

The company's inability to meet Nasdaq's requirements despite a 180-day extension suggests persistent underlying issues. Investors should closely monitor how this delisting affects Telesis Bio's market share and competitive position in the automated synthesis technology space, as well as any potential industry-wide implications for funding and valuation of biotech firms focused on therapeutic discovery tools.

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”) and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Telesis intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) to remove its Common Stock from listing on the Nasdaq Global Select Market on or about September 20, 2024. As a result, Telesis expects that the last trading day of its Common Stock on the Nasdaq Global Select Market will be on or about September 30, 2024. Telesis will remain subject to continued reporting obligations under Sections 13 and 15(d) of the Exchange Act.

As previously noted in the Company’s Current Report on Form 8-K filed with the SEC on April 8, 2024, Telesis received a letter on April 3, 2024 from the Listing Qualifications Department (the “Staff”) of Nasdaq notifying Telesis that the Company was not in compliance with the minimum stockholder’s equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders' equity for continued listing (the “Stockholders’ Equity Requirement”). The Company was granted a 180-day extension to regain compliance with the Stockholders’ Equity Requirement, which expires on September 30, 2024.

On June 12, 2024, Telesis also announced that on June 6, 2024, it received another letter from the Staff notifying the Company that the Market Value of Publicly Held Shares (“MVPHS”) of its common stock had been below the minimum of $5,000,000 for more than the previous 30 consecutive business days and as such the Company had failed to meet the minimum MVPHS of $5,000,000 (the “Minimum MVPHS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company was provided a period of 180 calendar days, or until December 3, 2024, to regain compliance with the Minimum MVPHS Requirement.

The Company believes that it will be unable to regain compliance with the Stockholders’ Equity Requirement or the Minimum MVPHS Requirement. As such, the Company has made the decision to voluntarily delist from Nasdaq. Following the delisting of the Common Stock from trading on Nasdaq, any trading in such securities would only occur in privately negotiated sales and potentially on an over-the-counter market. Telesis expects that its Common Stock will be quoted on a market operated by OTC Markets Group Inc. (the “OTC”) so that a trading market may continue to exist for such securities. There is no guarantee, however, that a broker will continue to make a market in Common Stock and that trading thereof will continue on an OTC market or otherwise.

About Telesis Bio

Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly^® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. Company products and technologies deliver virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com. Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the expected timing of the delisting from the Nasdaq Global Select Market, the deregistration of the Common Stock under Section 12(b) of the Exchange Act, including the filing of a Form 25, the expected last date on which trading in the Common Stock may take place on the Nasdaq Global Select Market, expected quotations of, trading in and market making in the Common Stock on an OTC market. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

Contact:
William J. Kullback
Chief Financial Officer
bill.kullback@telesisbio.com

FAQ

When will Telesis Bio (TBIO) delist from Nasdaq?

Telesis Bio (TBIO) expects to file Form 25 with the SEC on or about September 20, 2024, with the last trading day on Nasdaq Global Select Market expected to be around September 30, 2024.

Why is Telesis Bio (TBIO) delisting from Nasdaq?

Telesis Bio (TBIO) is delisting due to non-compliance with Nasdaq's minimum stockholder's equity requirement and minimum Market Value of Publicly Held Shares (MVPHS) requirement, which the company believes it cannot regain compliance with.

What will happen to Telesis Bio (TBIO) stock after delisting from Nasdaq?

After delisting from Nasdaq, Telesis Bio (TBIO) expects its common stock to be quoted on an OTC market operated by OTC Markets Group Inc., although there is no guarantee of continued trading or market-making activities.

Will Telesis Bio (TBIO) continue to report financial information after delisting?

Yes, Telesis Bio (TBIO) will remain subject to continued reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act of 1934, even after delisting from Nasdaq.